Keywords: Sarepta, Eteplirsen, Duchenne muscular dystrophy, Ph IIb extension trial

Sarepta rockets as eteplirsen seen to significantly benefit Duchenne patients

Article | 04 October 2012

Print This

US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) saw its shares rocket 200% to $44.93 by close of trading yesterday, when the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in